XML 80 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Income Taxes
12 Months Ended
Mar. 29, 2014
Income Taxes [Abstract]  
Income Taxes

17.      Income Taxes

 

Income before income taxes consisted of (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

March 29,

 

March 30,

 

March 31,

 

2014

 

2013

 

2012

United States

$

155,431 

 

$

200,124 

 

$

79,425 

Non-U.S.

 

306 

 

 

1,066 

 

 

558 

 

$

155,737 

 

$

201,190 

 

$

79,983 

 

 

The provision (benefit) for income taxes consists of (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

March 29,

 

March 30,

 

March 31,

 

2014

 

2013

 

2012

Current:

 

 

 

 

 

 

 

 

Federal

$

10,550 

 

$

3,537 

 

$

1,322 

State

 

258 

 

 

323 

 

 

518 

Non-U.S.

 

335 

 

 

243 

 

 

261 

Total current tax provision

$

11,143 

 

$

4,103 

 

$

2,101 

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

 

U.S.

 

36,543 

 

 

60,506 

 

 

(10,102)

Non-U.S.

 

(60)

 

 

(17)

 

 

Total deferred tax provision (benefit)

 

36,483 

 

 

60,489 

 

 

(10,101)

Total tax provision (benefit)

$

47,626 

 

$

64,592 

 

$

(8,000)

 

The effective income tax rates differ from the rates computed by applying the statutory federal rate to pretax income as follows (in percentages):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

March 29,

 

March 30,

 

March 31,

 

2014

 

2013

 

2012

Expected income tax provision at the U.S. federal statutory rate

 

35.0 

 

 

35.0 

 

 

35.0 

Valuation allowance changes affecting the provision of income taxes

 

(0.1)

 

 

(1.3)

 

 

(46.7)

Foreign taxes at different rates

 

0.1 

 

 

(0.1)

 

 

 -

R&D credit

 

(0.9)

 

 

(2.1)

 

 

 -

Stock compensation

 

(0.1)

 

 

0.1 

 

 

1.0 

Recognition of prior year benefit

 

(4.1)

 

 

 -

 

 

 -

Nondeductible expenses

 

0.5 

 

 

0.3 

 

 

0.1 

Other

 

0.2 

 

 

0.2 

 

 

0.6 

Provision (benefit) for income taxes

 

30.6 

 

 

32.1 

 

 

(10.0)

 

 

Significant components of our deferred tax assets and liabilities as of March 29, 2014 and March 30, 2013 are (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 29,

 

March 30,

 

2014

 

2013

Deferred tax assets:

 

 

 

 

 

Inventory valuation

$

7,692 

 

$

12,065 

Accrued expenses and allowances

 

3,905 

 

 

5,077 

Net operating loss carryforwards

 

29,062 

 

 

28,162 

Research and development tax credit carryforwards

 

15,164 

 

 

37,054 

State tax credit carryforwards

 

231 

 

 

237 

Capitalized research and development

 

3,485 

 

 

6,601 

Other

 

28,627 

 

 

21,505 

Total deferred tax assets

$

88,166 

 

$

110,701 

Valuation allowance for deferred tax assets

 

(32,159)

 

 

(23,232)

Net deferred tax assets

$

56,007 

 

$

87,469 

 

 

 

 

 

 

Deferred tax liabilities:

 

 

 

 

 

Depreciation and amortization

$

5,709 

 

$

5,238 

Acquisition intangibles

 

3,209 

 

 

623 

Total deferred tax liabilities

$

8,918 

 

$

5,861 

Total net deferred tax assets

$

47,089 

 

$

81,608 

 

These net deferred tax assets have been categorized on the Consolidated Balance Sheets as of March 29, 2014 and March 30, 2013 as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 29,

 

March 30,

 

2014

 

2013

Current deferred tax assets

$

22,024 

 

$

64,937 

Long-term deferred tax assets

 

25,065 

 

 

16,671 

Total net deferred tax assets

$

47,089 

 

$

81,608 

 

The current and long-term deferred tax assets are disclosed separately under their respective captions on the Consolidated Balance Sheets.

 

The valuation allowance increased by $8.9 million in fiscal year 2014 and decreased by $5.8 million in fiscal year 2013The increase during fiscal year 2014 was primarily due to the equity acquisition of Acoustic, which had a large Federal net operating loss that will not be fully realized due to the limitations of Internal Revenue Code Section 382.  The Company maintained its valuation allowance on various state net operating losses and credits due to the likelihood that they will expire or go unutilized because the Company no longer has a significant apportionment in the jurisdiction in which the attribute was created.  The decrease in the fiscal year 2013 allowance was the result of a release of valuation allowance that the Company had maintained on its capital loss carryforward due to the capital gain income generated by the sale of assets associated with the Company’s Apex products.  With regard to the remaining deferred tax assets, Management believes that the Company’s results from future operations will generate sufficient taxable income such that it is more likely than not that these deferred tax assets will be realized. 

 

At March 29, 2014, we had federal net operating loss carryforwards of $81.3 million.  Of that amount, $29.5 million related to acquired companies and are, therefore, subject to certain limitations under Section 382 of the Internal Revenue Code.  Because the Company has elected the “with and without” method for purposes of tracking its excess stock deductions, the amount of federal net operating loss included in deferred tax assets is $61.2 million, which yields a tax effected deferred tax asset of $21.4 million.  The net deferred tax asset for federal net operating loss carryforwards is $8.8 million after taking into account the valuation allowance that has been placed on this deferred tax asset.  The Company had $110.0 million of excess stock deductions which are not included in deferred tax assets.  The tax benefit from these deductions will increase additional paid-in capital when they are deemed realized under the “with and without” method.  We had net operating losses in various states that total $94.0 million. The federal net operating loss carryforwards expire in fiscal years 2019 through 2034.  The state net operating loss carryforwards expire in fiscal years 2015 through 2029.  We also have non-U.S. net operating losses of $2.2 million, which do not expire. 

 

Federal research and development credit carryforwards of $21.0 million expire in fiscal years 2018 through 2034.  Under the “with and without method”, all but $612 thousand of these credit carryforwards are deemed to have been utilized in fiscal year 2014 and are therefore, not reflected as deferred tax assets at the end of the fiscal year.  Of the $14.5 million of state research and development credits,  $2.8 million will expire in fiscal years 2022 through 2027.  The remaining $11.7 million of state research and development credits are not subject to expiration.    

 

We have approximately $307 thousand of cumulative undistributed earnings in certain non-U.S. subsidiaries.  We have not recognized a deferred tax liability on these undistributed earnings because the Company currently intends to reinvest these earnings in operations outside the U.S.  The unrecognized deferred tax liability on these earnings is approximately $109 thousand. 

 

We record unrecognized tax benefits for the estimated risk associated with tax positions taken on tax returns.  The unrecognized tax benefits balance was zero at March 29, 2014 and March 30, 2013.

 

The Company does not believe that its unrecognized tax benefits will significantly increase or decrease during the next 12 months.

 

We accrue interest and penalties related to unrecognized tax benefits as a component of the provision for income taxes.  As of March 29, 2014, the balance of accrued interest and penalties was zeroNo interest or penalties were incurred during fiscal year 2014 or 2013.  

 

The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions.  Fiscal years 2011 through 2014 remain open to examination by the major taxing jurisdictions to which we are subject.